Vivione Biosciences Inc. (TSX:VBI), through its wholly owned subsidiary,
Vivione Biosciences, LLC, announced today that it has entered into an
Agreement with Edelman, the world’s largest public relations firm, for
the firm to provide strategic communications development and support for
the biosciences company.
Edelman is comprised of 67 offices globally with more than 4,800
employees, and currently services over 1,025 clients in the U.S. ranging
from large corporations to small start-up companies. Vivione will
leverage Edelman's comprehensive approach to communications, integrating
traditional communications with digital and thought leadership
strategies, to maximize the company's exposure during a time of key
growth for its product, especially in new industry sectors such as the
Oil and Gas and Clinical markets. Edelman will be developing a
comprehensive communications plan that conveys the company’s vision and
goals to new audiences both domestically and internationally, while also
helping build Vivione’s global reputation with innovators and thought
leaders in the bioscience industry.
“We are excited to work with a world-renowned public relations firm like
Edelman,” said Vivione’s Chief Executive Officer, Kevin Kuykendall.
“Edelman’s global network of specialized public relations professionals
will help us develop key messaging initiatives, including press
releases, trade shows, interviews, and other marketing approaches as we
continue to commercialize RAPID-B into new markets. The timing of this
step is significant for us now that we are beginning to obtain key
certifications and launching innovative new products. Edelman’s ability
to enhance our media coverage and brand awareness will strengthen our
product awareness and accelerate our entry into the oil and gas and
clinical markets. We are confident Edelman will help us to get our
message out to potential customers and industry thought leaders.”
“We are looking forward to working closely with Vivione to introduce the
company and the RAPID-B System to key opinion leaders and decision
makers throughout the world. We are excited to be working with a company
whose technology has this kind of opportunity to revolutionize bacteria
detection across multiple industries, including the potential to save
lives,” said David Chamberlin, Executive Vice President and General
Manager of Edelman in Dallas.
Vivione is a TSX Venture Exchange listed biosciences company focused on
the commercialization of its proprietary RAPID-B system; an integrated
system of hardware, software and chemical reagents that quickly and
accurately identify, quantify and qualify bacteria and other pathogens
in food safety, bio-therapeutics, clinical, industrial and oil & gas
environments. For more information, visit www.VivioneBiosciences.com.
Edelman is the world’s largest public relations firm, with 67 offices
and more than 4,800 employees worldwide, as well as affiliates in more
than 30 cities. Edelman was named Advertising Age’s top-ranked PR firm
of the decade in 2009 and one of its “A-List Agencies” in both 2010 and
2011; Adweek’s “2011 PR Agency of the Year;” PRWeek’s “2011 Large PR
Agency of the Year;” and The Holmes Report’s “2013 Global Agency of the
Year” and its 2012 “Digital Agency of the Year.” Edelman was named one
of the “Best Places to Work” by Advertising Age in 2010 and 2012 and
among Glassdoor’s top ten “Best Places to Work” in 2011 and 2012.
Edelman owns specialty firms Edelman Berland (research), Blue
(advertising), BioScience Communications (medical communications), and
agencies Edelman Significa (Brazil), and Pegasus (China). Visit http://www.edelman.com
for more information. Edelman is an equal opportunity employer of all
protected classes, including veterans and individuals with disabilities.
This news release contains "forward-looking statements" within the
meaning of applicable securities laws. Although Vivione believes that
the expectations reflected in its forward-looking statements are
reasonable, such statements have been based on factors and assumptions
concerning future events that may prove to be inaccurate. These factors
and assumptions are based upon currently available information to
Vivione. Such statements are subject to known and unknown risks,
uncertainties and other factors that could influence actual results or
events and cause actual results or events to differ materially from
those stated, anticipated or implied in the forward-looking statements.
Readers are cautioned to not place undue reliance on forward-looking
statements. The statements in this press release are made as of the date
of this release and, except as required by applicable law, Vivione does
not undertake any obligation to publicly update or to revise any of the
included forward-looking statements, whether as a result of new
information, future events or otherwise. Vivione undertakes no
obligation to comment on analyses, expectations or statements made by
third-parties in respect of Vivione, or its financial or operating
results or (as applicable), their securities.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER
(AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE)
ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Copyright Business Wire 2014